cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Talaris Therapeutics Inc
1 watching
Current Price
$1.37
$0.05
(3.79%)
logo-tals
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
56.83M
52-Week High
52-Week High
10.56
52-Week Low
52-Week Low
0.89
Average Volume
Average Volume
0.28M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization56.83M
icon52-Week High10.56
icon52-Week Low0.89
iconAverage Volume0.28M
iconDividend Yield--
iconP/E Ratio--
What does the Talaris Therapeutics Inc do?
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Read More
How much money does Talaris Therapeutics Inc make?
News & Events about Talaris Therapeutics Inc.
Zolmax
3 months ago
HC Wainwright assumed coverage on shares of Talaris Therapeutics (NASDAQ:TALS Get Rating) in a report issued on Thursday, MarketBeat.com reports. The brokerage issued a buy rating and a $18.00 target price on the stock. Other equities analysts have also recently issued reports about the company. ...
Globe Newswire
1 year ago
Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients Initiated Phase 2 (FREEDOM-2) clinical trial for FCR001 in delayed tolerance induction patients BOSTON and LOUISVILLE, Ky., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ...
Benzinga
1 year ago
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. read more...
Frequently Asked Questions
Frequently Asked Questions
What is Talaris Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Talaris Therapeutics Inc shares?
plus_minus_icon
How can I buy Talaris Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Talaris Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Talaris Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Talaris Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Talaris Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Talaris Therapeutics Inc?
plus_minus_icon
What percentage is Talaris Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Talaris Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.37
$0.05
(3.79%)
logo-tals
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00